- Home
- CBL vs ANAB Comparison
CBL vs ANAB Comparison
Compare CBL & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CBL
- ANAB
- Stock Information
- Founded
- CBL 1978
- ANAB 2005
- Country
- CBL United States
- ANAB United States
- Employees
- CBL N/A
- ANAB N/A
- Industry
- CBL Real Estate Investment Trusts
- ANAB Biotechnology: Pharmaceutical Preparations
- Sector
- CBL Real Estate
- ANAB Health Care
- Exchange
- CBL Nasdaq
- ANAB Nasdaq
- Market Cap
- CBL 938.8M
- ANAB 1.0B
- IPO Year
- CBL 1993
- ANAB 2017
- Fundamental
- Price
- CBL $32.51
- ANAB $33.91
- Analyst Decision
- CBL
- ANAB Buy
- Analyst Count
- CBL 0
- ANAB 12
- Target Price
- CBL N/A
- ANAB $63.40
- AVG Volume (30 Days)
- CBL 102.1K
- ANAB 533.2K
- Earning Date
- CBL 11-06-2025
- ANAB 11-04-2025
- Dividend Yield
- CBL 5.53%
- ANAB N/A
- EPS Growth
- CBL 297.30
- ANAB N/A
- EPS
- CBL 4.02
- ANAB N/A
- Revenue
- CBL $553,643,000.00
- ANAB $169,467,000.00
- Revenue This Year
- CBL N/A
- ANAB $37.52
- Revenue Next Year
- CBL N/A
- ANAB N/A
- P/E Ratio
- CBL $8.06
- ANAB N/A
- Revenue Growth
- CBL 5.74
- ANAB 196.42
- 52 Week Low
- CBL $21.10
- ANAB $12.21
- 52 Week High
- CBL $33.54
- ANAB $40.96
- Technical
- Relative Strength Index (RSI)
- CBL 66.13
- ANAB 51.05
- Support Level
- CBL $29.07
- ANAB $32.90
- Resistance Level
- CBL $33.10
- ANAB $40.96
- Average True Range (ATR)
- CBL 0.68
- ANAB 2.54
- MACD
- CBL 0.29
- ANAB -0.73
- Stochastic Oscillator
- CBL 84.85
- ANAB 34.61
About CBL CBL & Associates Properties Inc.
CBL & Associates Properties Inc is a real estate investment trust. The company engages in the ownership, development, acquisition, leasing, management and operation of regional shopping malls, outlet centers, lifestyle centers, open-air centers and other properties. CBL's sales predominantly derive from leasing arrangements with retail tenants. The company also generates revenue from management and development fees, as well as sales of its real estate assets. CBL expands its portfolio of assets through activities such as redevelopment, renovation, and expansion.
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).